Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CCCC 
C4 Therapeutics Inc (CCCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CCCC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.8
1 Year Target Price $15.8
| 4 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.07% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 181.49M USD | Price to earnings Ratio - | 1Y Target Price 15.8 |
Price to earnings Ratio - | 1Y Target Price 15.8 | ||
Volume (30-day avg) 8 | Beta 2.98 | 52 Weeks Range 1.08 - 7.22 | Updated Date 08/28/2025 |
52 Weeks Range 1.08 - 7.22 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate -0.4 | Actual -0.37 |
Profitability
Profit Margin - | Operating Margin (TTM) -440.99% |
Management Effectiveness
Return on Assets (TTM) -22.8% | Return on Equity (TTM) -52.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31989702 | Price to Sales(TTM) 5.3 |
Enterprise Value 31989702 | Price to Sales(TTM) 5.3 | ||
Enterprise Value to Revenue 0.93 | Enterprise Value to EBITDA -0.42 | Shares Outstanding 71170800 | Shares Floating 50029524 |
Shares Outstanding 71170800 | Shares Floating 50029524 | ||
Percent Insiders 9.75 | Percent Institutions 76.91 |
Upturn AI SWOT
C4 Therapeutics Inc
Company Overview
History and Background
C4 Therapeutics, Inc. (CCCC) is a biopharmaceutical company founded in 2011. It focuses on developing novel small-molecule drugs that selectively target disease-causing proteins for degradation using targeted protein degradation (TPD). It emerged from research at Dana-Farber Cancer Institute and Yale University.
Core Business Areas
- Targeted Protein Degradation (TPD) Therapeutics: C4 Therapeutics develops small-molecule drugs that harness the cell's natural protein degradation machinery to eliminate disease-causing proteins.
- Oncology: The company's primary focus is on developing TPD-based therapeutics for the treatment of various cancers.
Leadership and Structure
Andrew Hirsch serves as the CEO. The company has a research and development-focused organizational structure.
Top Products and Market Share
Key Offerings
- CFT7455: An oral degrader of IKZF1/3, currently in clinical development for multiple myeloma and non-Hodgkin lymphomas. Estimated peak revenue potential is substantial if successful. Competitors in multiple myeloma include drugs from companies like Amgen (AMGN), Johnson & Johnson (JNJ), and Bristol Myers Squibb (BMY).
- Estimated market share or revenue: Information Not available
- CFT1946: A BRAF V600E degrader designed to address resistance mechanisms associated with BRAF inhibitors. Currently in Phase 1/2 trial. Competitors include BRAF inhibitors from Roche (ROG.SW) and Novartis (NVS).
- Estimated market share or revenue: Information Not available
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. TPD is an emerging field with significant potential.
Positioning
C4 Therapeutics is a leader in the TPD field, leveraging its expertise and proprietary platform to develop novel therapeutics. It faces competition from other companies developing TPD technologies.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is very large and continues to grow. The TPD field is an emerging area with a high potential impact. C4 Therapeutics is positioned to capture a share of this TAM if its drug candidates are successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary TPD platform
- Experienced management team
- Strong intellectual property portfolio
- Focus on high-value oncology targets
Weaknesses
- Dependence on successful clinical trial outcomes
- High cash burn rate
- Relatively small company size
- Limited number of commercialized products
Opportunities
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Advancements in TPD technology
- Positive clinical trial data for lead candidates
Threats
- Clinical trial failures
- Competition from other TPD companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- KYMR
- ARVN
- NUVL
Competitive Landscape
C4 Therapeutics competes in the targeted protein degradation space with other companies developing similar technologies. Its strengths lie in its proprietary platform and focus on oncology targets. Its disadvantages include its relatively small size and limited financial resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: C4 Therapeutics is in a growth phase, driven by the advancement of its clinical pipeline.
Future Projections: Future growth depends on the success of ongoing clinical trials and potential partnerships.
Recent Initiatives: Advancing CFT7455 and CFT1946 through clinical trials. Establishing collaborations with other pharmaceutical companies.
Summary
C4 Therapeutics is a biopharmaceutical company focused on targeted protein degradation with a pipeline of oncology drugs. Its future depends on successful clinical trials, particularly of CFT7455 and CFT1946. Potential threats include clinical trial failures and competition. They are in a high-growth, high-risk area, and its market position is highly reliant on future success. The company needs to carefully manage its cash burn.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available)
- Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About C4 Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-10-02 | CEO, President & Director Mr. Andrew J. Hirsch M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.c4therapeutics.com |
Full time employees 110 | Website https://www.c4therapeutics.com | ||
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.